Drs Tsujimoto and Yamamoto-Honda note that improvements in adherence are of benefit in terms of increasing uptake of proven antiplatelet therapy, but question the importance of the improvements in mean LDL-C level and SBP. In contrast to their suggestion, in high-risk cardiovascular patients there is clear evidence of benefits of blood pressure lowering in patients without hypertension and of more vs less blood pressure lowering1- 3; similarly, there are benefits of LDL-C level lowering in patients without hyperlipidemia and of more vs less LDL-C level lowering.4,5
© 2001-2024 Fundación Dialnet · Todos los derechos reservados